APOA1 and rheumatic disorder: Biological therapies demonstrated an atheroprotective effect via maintaining the level of reverse cholesterol transport (RCT) proteins or anti-atherogenic lipid apoA1 (30, 31), while different anti-rheumatic disease medications have varying effects on lipid metabolism.